Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
660
datasets available to search
ShareScore release 0.9.0
Dataset results
660 results for “alcohol use”
Data for manuscript Marmet, Studer, Lemoine, Grazioli, Bertholet & Gmel (2019). Reconsidering the associations between self-reported alcohol use disorder and mental health problems in the light of co-occurring addictions in young Swiss men. Plos One. DOI: 10.1371/journal.pone.0222806.
<p>Dataset for the manuscript Marmet, Studer, Lemoine, Grazioli, Bertholet & Gmel (2019). Reconsidering the associations between self-reported alcohol use disorder and mental health problems in the light of co-occurring addictions in young Swiss men. Plos One. DOI: 10.1371/journal.pone.0222806.</p> <p>The dataset contains all data needed to reproduce the results in the above cited manuscript. Variable description and labels can be found in the codebook. For further information on the instruments used please refer to the manuscript.</p> <p>The data was collected between April 2016 and March 2018 in Switzerland by the C-SURF study (<a href="http://www.c-surf.ch">www.c-surf.ch</a>). Participants were on average 25 years old when they answered the questionnaires. The final sample size used in the manuscript is 5516. Please note that the dataset contains 25 datasets created with multiple imputation, therefore there are no missing values in the dataset.</p> <p>The research protocol for this study was approved by the Human Research Ethics Committee of the Canton Vaud (Protocol No. 15/07). Data collection was funded by the Swiss National Science Foundation (FN 33CSC0-122679, FN 33CS30_139467, FN 33CS30_148493)</p>
Data for the paper Lemoine, Gmel, Foster, Marmet, Studer (2020). Multiple trajectories of alcohol use and the development of alcohol use disorder: do Swiss men mature-out of problematic alcohol use during emerging adulthood? Plos One. https://doi.org/10.1371/journal.pone.0220232
<p>Data for the paper Lemoine, Gmel, Foster, Marmet, Studer (2020). Multiple trajectories of alcohol use and the development of alcohol use disorder: do Swiss men mature-out of problematic alcohol use during emerging adulthood?</p> <p>Plos One. <a href="https://doi.org/10.1371/journal.pone.0220232">https://doi.org/10.1371/journal.pone.0220232</a></p> <p>Please refer to the paper for further information about the data.</p> <p> </p> <p>The dataset contains all data needed to reproduce the results in the above cited paper. Variable description and labels can be found in the codebook. For further information on the instruments used please refer to the paper.</p> <p>The dataset contains data for three waves that was collected between September 2010 and March 2018 in Switzerland by the C-SURF study (<a href="http://www.c-surf.ch/">www.c-surf.ch</a>). Participants were on average 20 years old at wave 1, 21 at wave 2 and 25 at wave 3 when they answered the questionnaires. The final sample size used in the paper is 4746 after excluding those that did not reply to a questionnaire or to a variable of interest for the main analysis.</p> <p>The research protocol for this study was approved by the Human Research Ethics Committee of the Canton Vaud (Protocol No. 15/07). Data collection was funded by the Swiss National Science Foundation (FN 33CSC0-122679, FN 33CS30_139467, FN 33CS30_148493).</p>
Data for Are Changes in Alcohol Use and Personality Traits associated? A Cohort Study among Young Swiss Men
<p>These are the data and metadata for the article </p> <p><strong>Are Changes in Alcohol Use and Personality Traits associated? A Cohort Study among Young Swiss Men</strong></p> <p>by </p> <p><strong>Gerhard Gmel, Simon Marmet, Joseph Studer, and Matthias Wicki</strong></p> <p><strong>to be published in Frontiers of Psychiatry</strong></p>
Heterogeneous Biocatalytic Reduction of 5-(Hydroxy)methyl Furfural Using two Co-immobilised Alcohol Dehydrogenases
<p>Biocatalyst heterogenisation may enable robust processes that can be applied in biorefineries to selectively valorise highly functionalised platform chemicals. In this work, we co-immobilise two dehydrogenases and successfully apply them in the selective reduction of 5-hydroxymethylfurfural (HMF) to 2,5-bis(hydroxymethyl) furan (BHMF) with efficient <em>in situ</em> cofactor regeneration. First, we select the best enzyme candidates (an alcohol dehydrogenase from <em>Escherichia coli</em> together with a thermostable glucose dehydrogenase from <em>Bacillus subtilis</em>) and then screen a variety of carriers and chemistries to find the optimal individual immobilisation protocols for each dehydrogenase. As a result, methacrylate carriers (Purolite™) functionalised with either aldehydes or with epoxy and cobalt-chelate groups co-immobilise both enzymes in high yields with a sufficient activity recovery (>20%). These optimal heterogeneous biocatalysts enable the quantitative bio-reduction of HMF to BHMF with >99% selectivity in only fifteen minutes, exhibiting an outstanding reusability of >15 batch cycles with a total volumetric productivity of ∼5 g L<sup>−1</sup> h<sup>−1</sup> of BHMF. Preliminary experiments on a semipreparative scale with HMF loadings of 40 mM also reach high product conversions (86%). Overall, the judicious selection of enzymes, carriers and reaction conditions enables the design of robust biocatalysts that may contribute to paving the way to the valorisation of highly functionalised chemicals in biorefineries.</p>
GDNF gene therapy for alcohol use disorder in male non-human primates
<p>These the minimal data sets that were utilized in analysis and interpretation for the manuscript "GDNF gene therapy treatment for alcohol use disorder" by Matthew Ford et al. These data sets were collected during a study to evaluate the utility of viral-based GDNF expression in the ventral tegmental area to reduce alcohol intake and prevent relapse in a primate model of alcohol use disorder, and ultimately the feasibility of GDNF as a gene therapy for alcohol use disorder. There are data sets on behavior, biochemical analyses, and cyclic voltammetry.</p>
CAP: Doxazosin in the Treatment of Co-Occurring PTSD and Alcohol Use Disorders
ClinicalTrials.gov study NCT02500602. IPD Sharing: YES. Countries: 1. Publications: 1.
Mental health and alcohol use among patients attending a post-COVID-19 follow-up clinic: A cohort study.
<p>Study dataset</p> <p>Abstract</p> <p><strong>Background:</strong> Ongoing mental health problems following COVID-19 infection warrant greater examination. This study aimed to investigate psychiatric symptoms and problematic alcohol use among Long COVID patients.<br> <br> <strong>Methods: </strong>The study was conducted at the Mater Misericordiae University Hospital’s post-COVID-19 follow-up clinic in Dublin, Ireland. A prospective cohort study design was used encompassing assessment of patients’ outcomes at 2-4 months following an initial clinic visit (Time 1), and 7–14-month follow-up (Time 2). Outcomes regarding participants’ demographics, acute COVID-19 healthcare use, mental health, and alcohol use were examined.<br> <br> <strong>Results: </strong>The baseline sample’s (n = 153) median age = 43.5yrs (females = 105 (68.6%)). Sixty-seven of 153 patients (43.8%) were admitted to hospital with COVID-19, 9/67 (13.4%) were admitted to ICU, and 17/67 (25.4%) were readmitted to hospital following an initial COVID-19 stay. Sixteen of 67 (23.9%) visited a GP within seven days of hospital discharge, and 26/67 (38.8%) did so within 30 days. Seventeen of 153 participants (11.1%) had a pre-existing affective disorder. The prevalence of clinical range depression, anxiety, and PTSD scores at Time 1 and Time 2 (n = 93) ranged from 12.9% (Time 1 anxiety) to 22.6% (Time 1 PTSD). No statistically significant differences were observed between Time 1 and Time 2 depression, anxiety, and PTSD scores. Problematic alcohol use was common at Time 1 (45.5%) and significantly more so at Time 2 (71.8%). Clinical range depression, anxiety, and PTSD scores were significantly more frequent among acute COVID-19 hospital admission and GP attendance (30 days) participants, as well as among participants with lengthy ICU stays, and those with a previous affective disorder diagnosis.<br> <br> <strong>Conclusions: </strong>Ongoing psychiatric symptoms and problematic alcohol use in Long COVID populations are a concern and these issues may be more common among individuals with severe acute COVID-19 infection and /or pre-existing mental illness.</p>
Reductive synthesis of azoxypyridines from nitropyridines using hydroxides in alcoholic media by L. Caruana et al. - Raw NMR data
<p>NMR raw data for the work "Reductive synthesis of azoxypyridines from nitropyridine using hydroxides in alcoholic media"</p>
Addressing Heavy Alcohol Use Consumption With Kudzu
ClinicalTrials.gov study NCT03709043. IPD Sharing: NO. Countries: 1. Publications: 0.
Transcranial Magnetic Stimulation for the Treatment of Veterans With Alcohol Use Disorders
ClinicalTrials.gov study NCT03191266. IPD Sharing: YES. Countries: 1. Publications: 1.
Reducing Alcohol Use & Post-traumatic Stress Disorder (PTSD) With Cognitive Restructuring & Experiential Acceptance
ClinicalTrials.gov study NCT00760994. IPD Sharing: Not stated. Countries: 1. Publications: 14.
Piloting "Signs of Safety": A Deaf-Accessible Therapy Toolkit for Alcohol Use Disorder and Trauma
ClinicalTrials.gov study NCT03845985. IPD Sharing: YES. Countries: 1. Publications: 1.
Glutamatergic Modulation of Disordered Alcohol Use
ClinicalTrials.gov study NCT02539511. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Biobehavioral Pathways Underlying Alcohol Use and Health
ClinicalTrials.gov study NCT05135767. IPD Sharing: YES. Countries: 1. Publications: 0.
Risperidone Long-acting Versus Oral Risperidone in Patients With Schizophrenia and Alcohol Use Disorder
ClinicalTrials.gov study NCT00130923. IPD Sharing: Not stated. Countries: 1. Publications: 27.
Modulating the Impact of Critical Events in Early HIV Infection: Effect of ART Initiation and Alcohol Use
ClinicalTrials.gov study NCT02744040. IPD Sharing: NO. Countries: 1. Publications: 1.
Internet-based Videoconferencing to Address Alcohol Use and Pain
ClinicalTrials.gov study NCT03982433. IPD Sharing: NO. Countries: 1. Publications: 1.
Building and Pilot Testing a Couples-based Smartphone Systems to Address Alcohol Use Disorder
ClinicalTrials.gov study NCT04059549. IPD Sharing: NO. Countries: 1. Publications: 1.
Computer-based Intervention for Alcohol-using HIV/HCV+ Women
ClinicalTrials.gov study NCT03362476. IPD Sharing: YES. Countries: 2. Publications: 3.
Varenicline and Bupropion for Alcohol Use Disorder
ClinicalTrials.gov study NCT04167306. IPD Sharing: Not stated. Countries: 1. Publications: 2.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.